12:53:26 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017


ListaOB Match
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2022-03-29 09:37:16
Moss, 29 March 2022

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative
and efficient diagnostics for better treatment decisions, is pleased to announce
the release of the novel CE marked SARS-CoV-2 Total Antibody Immunoassay. This
is an open channel immunoassay for use on high-throughput clinical chemistry

"The need for reliable high-throughput antibody tests increases in the
post-vaccine phase of the COVID-19 pandemic, to follow, document and manage
efficient population immunity. With up to 2,000 tests per hour we are confident
that our new SARS-CoV-2 test can increase capacity and laboratory efficiency
significantly. Our assay can be used on all instrument platforms with no
additional infrastructure or workflow costs.", says CEO Hilja Ibert in Gentian

Gentian's SARS-CoV-2 Total Antibody Immunoassay captures the full immune
response detecting total antibody levels targeting the S1-subunit of SARS-CoV-2.
The assay is fully aligned with the WHO International Standard for quantitative

The Gentian assay is easily accessible and efficient and is intended to identify
patients with an adaptive immune response to SARS-CoV-2 that indicates recent or
prior infection or a successful response to vaccination. It will provide a
powerful high-throughput test for community management of COVID-19 through
long-term monitoring of natural and vaccine-related immune response, with the
potential to aid future vaccination evaluation and strategy.

Gentian's turbidimetric SARS-CoV-2 Total Antibody Immunoassay has been developed
in collaboration with the University in Tromsø (UiT). The SARS-CoV-2 test will
add to Gentian's diagnostics test portfolio including four established products,
and the GCAL® infection and inflammation assay which is in market development.
Initial market focus will be on the Nordic countries, with subsequent commercial
expansion into additional European geographies.

For further information, please contact:
Hilja Ibert, CEO
+47 919 05 242 (mobile)

Njaal Kind, CFO and COO
+47 919 06 525 (mobile)

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.